focus -WSS

focus

author：entertainment 2025-09-06 09:57:10 - browse：323

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Regeneron agrees to White House price limits on anti

hotspot

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

Designating disabled people as health disparity population is crucial

New Covid vaccine is recommended for everyone 6 months or older

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Generate Biomedicines machine learning biotech raises $273M

leisure time

focus

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Generative AI mines health records to identify patients’ social needs

Drug repurposing or repositioning? The language matters

New Covid vaccine is recommended for everyone 6 months or older

Psychedelics group wrestles with new pharma identity

Food makers tried to stack nutrition panel with preferred experts

In Memoriam: Notable people who died in 2023

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Medicare proposal to cover medical devices draws a mixed reaction

GSK to buy asthma

Wikipedia

New weight loss drugs vying to be the next Wegovy or Mounjaro

How to make the FDA’s new prescription one

Doulas covered by Medicaid under New York's new plan

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Heart disease and mental health: A look at cardiac psychology

As JPM 2024 winds down, some health tech firms project optimism

knowledge

hotspot

explore

entertainment